Researchers at Stanford have developed a method for identifying a subject that is at risk of progression to clinically significant COVID-19 infection or disease.
Dr. Curt Scharfe and colleagues have developed RUSPseq, a method for next generation molecular testing originally conceived to diagnose metabolic disorders in newborns.